

Company No. 12615561

GSK FINANCE (NO.3) LIMITED

REDUCTION OF SHARE CAPITAL

SOLVENCY STATEMENT FOR THE PURPOSES OF SECTION 642 OF THE COMPANIES
ACT 2006


We, being all of the directors of the Company as at the date of this statement, having taken account of all of the Company's liabilities (including any contingent or prospective liabilities), have each formed the opinion that:

1. as regards the Company's situation at the time of this statement, there is no ground on which the Company could be found unable to pay (or otherwise discharge) its debts; and
2. the Company will be able to pay (or otherwise discharge) its debts in full within 12 months of the commencement of a winding up.

Signed by each of the directors on 21 March 2024




.....
Peter Hopkins



.....
Alistair Davidson



.....
Darren Barnett,
Authorised Signatory
Representing The Wellcome Foundation Limited
Corporate Director



.....
Marcus Dowding
Authorised Signatory
Representing Edinburgh Pharmaceutical Industries Limited
Corporate Director